Overview Dividends

(MD) Mednax - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US58502B1061

Neonatology, Maternal-Fetal, Pediatric, Hospitalist, Surgery

Health Care Services
Market Cap in USD: 1,905m

IPO / Inception: 1995-09-19
Return 12m vs S&P 500: 38.2%

EPS (Earnings per Share)

EPS CAGR: -45.94%
EPS Trend: -5.8%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: -0.30%
Rev. Trend: -21.3%

Last SUE: 1.25
Qual. Beats: 1

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	46.0%
Value at Risk 5%th	64.2%
Relative Tail Risk	-15.11%

Reward TTM
Sharpe Ratio	1.11
Alpha	46.80
CAGR/Max DD	0.21

Character TTM
Hurst Exponent	0.579
Beta	0.764
Beta Downside	0.934

Drawdowns 3y
Max DD	59.49%
Mean DD	24.20%
Median DD	19.12%

Description: MD Mednax November 16, 2025

Pediatrix Medical Group, Inc. (formerly MEDNAX) delivers a spectrum of pediatric and perinatal services across U.S. hospitals, including NICU care for premature or high-risk newborns, maternal-fetal medicine for expectant mothers, and broader pediatric subspecialties such as intensive care, surgery, and emergency medicine. Its clinical model relies on physician subspecialists, nurse practitioners, and allied health professionals who operate within neonatal units, labor-and-delivery suites, and pediatric departments.

In FY 2023 the company reported roughly $2.3 billion in revenue with an adjusted EBITDA margin near 7 %, reflecting steady demand for high-complexity neonatal services. Volume growth in NICU admissions has averaged 4 % YoY, driven by a modest rise in U.S. preterm birth rates (≈10 % of all births) and increasing referral patterns to specialized centers. A key economic driver is the payer mix: about 55 % of revenue comes from Medicare/Medicaid, making the business sensitive to policy changes in reimbursement rates and bundled-payment initiatives targeting perinatal care.

For a deeper, data-rich perspective on MD’s valuation dynamics, you may find ValueRay’s analytical tools helpful.

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income (162.2m TTM) > 0 and > 6% of Revenue (6% = 115.3m TTM)

FCFTA 0.12 (>2.0%) and ΔFCFTA 6.88pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 16.89% (prev 7.73%; Δ 9.16pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.13 (>3.0%) and CFO 290.0m > Net Income 162.2m (YES >=105%, WARN >=100%)

Net Debt (302.2m) to EBITDA (258.3m) ratio: 1.17 <= 3.0 (WARN <= 3.5)

Current Ratio 1.83 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (85.6m) change vs 12m ago 1.29% (target <= -2.0% for YES)

Gross Margin 25.81% (prev 21.27%; Δ 4.54pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 89.91% (prev 96.64%; Δ -6.72pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 7.57 (EBITDA TTM 258.3m / Interest Expense TTM 31.1m) >= 6 (WARN >= 3)

Altman Z'' 1.44

(A) 0.15 = (Total Current Assets 717.2m - Total Current Liabilities 392.5m) / Total Assets 2.20b

(B) -0.05 = Retained Earnings (Balance) -116.8m / Total Assets 2.20b

(D) -0.09 = Book Value of Equity -115.5m / Total Liabilities 1.31b

Total Rating: 1.44 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 72.52

1. Piotroski 7.0pt

2. FCF Yield 12.39%

3. FCF Margin 14.22%

4. Debt/Equity 0.72

5. Debt/Ebitda 1.17

6. ROIC - WACC (= 6.75)%

7. RoE 19.79%

8. Rev. Trend -21.31%

9. EPS Trend -5.82%

What is the price of MD shares?

As of January 03, 2026, the stock is trading at USD 21.29 with a total of 573,925 shares traded.
Over the past week, the price has changed by -2.65%, over one month by -10.58%, over three months by +24.94% and over the past year by +63.39%.

Is MD a buy, sell or hold?

Mednax has received a consensus analysts rating of 3.75. Therefor, it is recommend to hold MD.

Strong Buy: 3
Buy: 0
Hold: 5
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the MD price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	22.7	6.5%
Analysts Target Price	22.7	6.5%
ValueRay Target Price	23.7	11.5%

MD Fundamental Data Overview December 28, 2025

Market Cap USD = 1.90b (1.90b USD * 1.0 USD.USD)
P/E Trailing = 11.4503
P/E Forward = 9.1158
P/S = 0.9907
P/B = 2.1
P/EG = 0.88
Beta = 0.769
Revenue TTM = 1.92b USD
EBIT TTM = 235.2m USD
EBITDA TTM = 258.3m USD
Long Term Debt = 577.2m USD (from longTermDebt, last quarter)
Short Term Debt = 37.6m USD (from shortTermDebt, last quarter)
Debt = 642.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 302.2m USD (from netDebt column, last quarter)
Enterprise Value = 2.21b USD (1.90b + Debt 642.3m - CCE 340.1m)
Interest Coverage Ratio = 7.57 (Ebit TTM 235.2m / Interest Expense TTM 31.1m)
FCF Yield = 12.39% (FCF TTM 273.4m / Enterprise Value 2.21b)
FCF Margin = 14.22% (FCF TTM 273.4m / Revenue TTM 1.92b)
Net Margin = 8.44% (Net Income TTM 162.2m / Revenue TTM 1.92b)
Gross Margin = 25.81% ((Revenue TTM 1.92b - Cost of Revenue TTM 1.43b) / Revenue TTM)
Gross Margin QoQ = 28.48% (prev 26.60%)
Tobins Q-Ratio = 1.00 (Enterprise Value 2.21b / Total Assets 2.20b)
Interest Expense / Debt = 0.48% (Interest Expense 3.06m / Debt 642.3m)
Taxrate = 18.31% (16.1m / 87.8m)
NOPAT = 192.2m (EBIT 235.2m * (1 - 18.31%))
Current Ratio = 1.83 (Total Current Assets 717.2m / Total Current Liabilities 392.5m)
Debt / Equity = 0.72 (Debt 642.3m / totalStockholderEquity, last quarter 890.7m)
Debt / EBITDA = 1.17 (Net Debt 302.2m / EBITDA 258.3m)
Debt / FCF = 1.11 (Net Debt 302.2m / FCF TTM 273.4m)
Total Stockholder Equity = 819.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.37% (Net Income 162.2m / Total Assets 2.20b)
RoE = 19.79% (Net Income TTM 162.2m / Total Stockholder Equity 819.6m)
RoCE = 16.84% (EBIT 235.2m / Capital Employed (Equity 819.6m + L.T.Debt 577.2m))
RoIC = 13.45% (NOPAT 192.2m / Invested Capital 1.43b)
WACC = 6.70% (E(1.90b)/V(2.55b) * Re(8.83%) + D(642.3m)/V(2.55b) * Rd(0.48%) * (1-Tc(0.18)))
Discount Rate = 8.83% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.94%
[DCF Debug] Terminal Value 78.93% ; FCFE base≈210.1m ; Y1≈259.2m ; Y5≈442.2m
Fair Price DCF = 75.50 (DCF Value 6.48b / Shares Outstanding 85.9m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -5.82 | EPS CAGR: -45.94% | SUE: -4.0 | # QB: 0
Revenue Correlation: -21.31 | Revenue CAGR: -0.30% | SUE: 1.25 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.38 | Chg30d=+0.032 | Revisions Net=+2 | Analysts=5
EPS next Year (2026-12-31): EPS=2.19 | Chg30d=+0.360 | Revisions Net=+6 | Growth EPS=+4.9% | Growth Revenue=+2.7%

Additional Sources for MD Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle